Performance Status During Treatment With Pemetrexed in Patients With NSCLC
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The primary research objective of this observational study in pretreated patients with NSCLC
of Stage IIIa/b or Stage IV is to evaluate patients' Karnofsky Index (KI) after the second
cycle of second-line treatment with single agent pemetrexed in a real life setting, and to
evaluate factors potentially influencing performance status in terms of KI, i.e. frequency of
use of concomitant medications, in particular analgesics, folic acid, Vitamin B12,
antiemetics, and medications against diarrhea; as documented in patient diary (days of use
per week) and by the physicians.